


Slow release of a drug, TT-10, improves heart attack recovery in a mouse model

October 22 2021



Jianyi "Jay" Zhang. Credit: UAB

A heart attack kills heart muscle cells, leading to a scar that weakens the heart, often leading to eventual heart failure. The lack of muscle repair is due to the very limited ability of mammalian heart muscle cells to

proliferate, except for a brief period around birth.

Thus, a pharmaceutical product called TT-10, which acts through components of the Hippo-Yap signaling pathway to spur proliferation of heart muscle [cells](#), was thought to offer promise to treat heart attacks. Intraperitoneal injections of TT-10 in a mouse heart-attack model several years ago at first promoted proliferation of heart muscle cells and showed declines in the size of the dead area of heart muscle, known as an infarct, one week after administration. However, those early improvements were followed by worsened [cardiac function](#) at later time points.

So, Jianyi "Jay" Zhang, M.D., Ph.D., and his University of Alabama at Birmingham Department of Biomedical Engineering colleagues asked a simple question: What would happen if TT-10 were loaded into [nanoparticles](#) made of poly-lactic-co-glycolic-acid, or PLGA, which would then allow the slow release of TT-10?

Slow release indeed turned out to be beneficial, as Zhang and UAB colleagues report in the journal *JCI Insight*. Nanoparticle-mediated, slow-release delivery of TT-10 enhanced the potency and durability of TT-10 treatment for repair of heart muscle in the mouse heart-attack model.

Injection of the TT-10 nanoparticles into the infarcted heart muscle improved heart function—as measured by significantly improved ejection fractions and functional shortening, and significant decreases in end-systolic diameters and end-diastolic diameters—as compared with groups of mice treated with saline, empty nanoparticles or direct TT-10 solution. Also, the TT-10 nanoparticle-treated hearts had significantly lower infarct sizes and lower heart-weight/body-weight ratios compared to the other three groups, which all had similar measurements. All these measures indicated improved heart function for the TT-10 nanoparticle group.

The researchers also measured the effects of TT-10 on the biology of heart [muscle](#) cells, known as cardiomyocytes, and on several markers of cell reproduction, both in culture and in the mouse [heart-attack](#) model.

Human induced pluripotent stem-cell cardiomyocytes grown in different concentrations of TT-10 showed increased molecular markers for proliferation, the S-phase of the cell cycle (when the cell replicates its genome content), the M-phase of the cell cycle (when the cell divides the copied DNA) and cytokinesis (when the cytoplasm of the two daughter cells is split in two). Peak activity was seen at TT-10 concentrations of 10 to 20 micromolar.

The cultured cardiomyocytes also showed significantly reduced programmed cell death, or apoptosis, and a significantly increased proportion of cardiomyocytes with the transcriptional co-activator Yap located in the nuclei. That presence of Yap in the nucleus, where it actively aids gene expression, is consistent with a role for Hippo-Yap signaling in cardiac regeneration, Zhang says.

Hearts treated with TT-10 nanoparticles in the mouse [heart-attack](#) model had dramatically more border-zone cardiomyocytes that showed markers for cell proliferation, M-phase growth and nuclear location of Yap at one week after infarction, compared to the other three treatment groups. The border zone is the area next to the infarct. Also, the TT-10 nanoparticle treatment appeared to promote blood vessel growth, called angiogenesis.

This suggests that the improvements in myocardial recovery observed in TT-10 nanoparticle-treated mice appeared to be, at least partially, attributable to the activation of Hippo-Yap signaling and cardiomyocyte proliferation, the UAB researchers say.

"Thus, our results suggest that PLGA nanoparticles could be used to improve the efficiency of treatment administration for numerous

cardiovascular drugs," Zhang said. "Furthermore, although the animals in our current investigation were treated with TT-10 nanoparticles via direct intramyocardial injections during open-chest surgery, PLGA nanoparticles are fully compatible with less invasive clinical delivery methods, such as catheter-based or echo-guided transthoracic myocardial injection."

Co-authors with Zhang in the study, "TT-10-loaded nanoparticles promote cardiomyocyte proliferation and cardiac repair in a mouse model of myocardial infarction," are Wangping Chen, Danielle Pretorius, Yang Zhou and Yuji Nakada, UAB Department of Biomedical Engineering; and Jinfu Yang, Second Xiangya Hospital, Central South University, Changsha, China. Chen is a visiting scholar from Second Xiangya Hospital, Central South University.

More information: Wangping Chen et al, TT-10–loaded nanoparticles promote cardiomyocyte proliferation and cardiac repair in a mouse model of myocardial infarction, *JCI Insight* (2021). [DOI: 10.1172/jci.insight.151987](https://doi.org/10.1172/jci.insight.151987)

Provided by University of Alabama at Birmingham

Citation: Slow release of a drug, TT-10, improves heart attack recovery in a mouse model (2021, October 22) retrieved 6 April 2023 from <https://medicalxpress.com/news/2021-10-drug-tt-heart-recovery-mouse.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--